Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Revive Therapeutics Ltd (RVVTF)

Revive Therapeutics Ltd (RVVTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases ACCESS Newswire - Wed Mar 11, 2:30AM CDT

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study GlobeNewswire - Mon Dec 15, 2025

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study GlobeNewswire - Fri Nov 21, 2025

TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Announces Closing of Second Tranche of Private Placement GlobeNewswire - Fri Sep 19, 2025

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Announces Extension of Proposed Private Placement GlobeNewswire - Fri Sep 5, 2025

TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement GlobeNewswire - Mon Aug 11, 2025

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“ Revive ” or the “ Company ”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to...

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement GlobeNewswire - Wed Jul 30, 2025

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study GlobeNewswire - Tue Jul 8, 2025

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity GlobeNewswire - Thu Jun 26, 2025

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)
Revive Therapeutics Advances with Next-Generation Bucillamine Development GlobeNewswire - Wed Jun 4, 2025

RVV.CN : 0.0400 (unch)
RVVTF : 0.0328 (+7.89%)

Barchart Exclusives

This Space Stock Just Proved the Bears Wrong Again—Here's What Comes Next Barchart - 37 minutes ago
AST SpaceMobile’s recent dip highlights how short-term setbacks can obscure long-term progress, especially as major regulatory wins reshape its competitive position. The key question now is execution—not viability. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.